Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012558 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Mitch Brinkkemper und 28 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection prevention, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: HIV-1, HIV Antibodies, env Gene Products, Human Immunodeficiency Virus, AIDS Vaccines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, NIAID NIH HHS, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
An effective human immunodeficiency virus 1 (HIV-1) vaccine will most likely have to elicit broadly neutralizing antibodies (bNAbs) to overcome the sequence diversity of the envelope glycoprotein (Env). So far, stabilized versions of Env, such as SOSIP trimers, have been able to induce neutralizing antibody (NAb) responses, but those responses are mainly strain-specific. Here we attempted to broaden NAb responses by using a multivalent vaccine and applying a number of design improvements. First, we used highly stabilized SOSIP.v9 trimers. Second, we removed any holes in the glycan shields and optimized glycan occupancy to avoid strain-specific glycan hole responses. Third, we selected five sequences from the same clade (B), as we observed previously that combining Env trimers from clade A, B and C did not improve cross-reactive responses, as they might have been too diverse. Fourth, to improve antibody (Ab) responses, the Env trimers were displayed on two-component I53-50 nanoparticles (NPs). Fifth, to favor activation of cross-reactive B cells, the five Env trimers were co-displayed on mosaic NPs. Sixth, we immunized rabbits four times with long intervals between vaccinations. These efforts led to the induction of cross-reactive B cells and cross-reactive binding Ab responses, but we only sporadically detected cross-neutralizing responses. We conclude that stabilized HIV-1 Env trimers that are not modified specifically for priming naive B cells are unable to elicit strong bNAb responses, and infer that sequential immunization regimens, most likely starting with specific germline-targeting immunogens, will be necessary to overcome Env’s defenses against the induction of NAbs. The antigens described here could be excellent boosting immunogens in a sequential immunization regimen, as responses to bNAb epitopes were induced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection prevention, Amsterdam, The Netherlands.
- Amsterdam institute for Infection and Immunity, Infectious diseases, Amsterdam, The Netherlands.
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
- School of Biological Sciences, University of Southampton, Southampton, United Kingdom.
- Duke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America.
- Department of Biochemistry, University of Washington, Seattle, Washington, United States of America.
ORCID-Profile: Mitch Brinkkemper, Rogier W Sanders
Förderung
- Gates Foundation
- NIAID NIH HHS
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Bill and Melinda Gates Foundation
- national institute for health
- The Fondation Dormeur, Vaduz
- Amsteram UMC
Zitieren
APA
Brinkkemper, M., Kerster, G., Brouwer, P. J. M., Tran, A. S., Torres, J. L., Ettema, R. A., Nijhuis, H., Allen, J. D., Zhu, W., Gao, H., Lee, W. H., Bijl, T. P. L., Snitselaar, J. L., Burger, J. A., Bontjer, I., Olijhoek, W., Ravichandran, R., van Breemen, M. J., Del Moral-Sánchez, I., …, & Sanders, R. W. (2024). Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012558
Vancouver
Brinkkemper M, Kerster G, Brouwer PJM, Tran AS, Torres JL, Ettema RA, et al. Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012558
BibTeX
@article{Brinkkemper2024,
author = {Brinkkemper, Mitch and Kerster, Gius and Brouwer, Philip J M and Tran, Andy S and Torres, Jonathan L and Ettema, Roos A and Nijhuis, Haye and Allen, Joel D and Zhu, Wenwen and Gao, Hongmei and Lee, Wen-Hsin and Bijl, Tom P L and Snitselaar, Jonne L and Burger, Judith A and Bontjer, Ilja and Olijhoek, Wouter and Ravichandran, Rashmi and van Breemen, Marielle J and Del Moral-Sánchez, Iván and Derking, Ronald and Sliepen, Kwinten and Ozorowski, Gabriel and Crispin, Max and Montefiori, David C and Claireaux, Mathieu and Ward, Andrew B and van Gils, Marit J and King, Neil P and Sanders, Rogier W},
title = {Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012558}
}
EUVIMED